US 12,378,219 B2
Crystalline forms of a MAGL inhibitor
Thomas Vetter, Valby (DK); John J. M. Wiener, San Diego, CA (US); Cheryl A. Grice, Redwood City, CA (US); Daniel J. Buzard, San Diego, CA (US); Justin S. Cisar, San Diego, CA (US); Olivia Delene Weber, San Diego, CA (US); Amy Allan, San Diego, CA (US); Nicholas Raffaele, SanDiego, CA (US); Jeanne V. Moody, San Diego, CA (US); and Michael B. Shaghafi, San Diego, CA (US)
Assigned to H. LUNDBECK A/S, Valby (DK)
Filed by H. LUNDBECK A/S, Valby (DK)
Filed on May 3, 2023, as Appl. No. 18/311,759.
Claims priority of provisional application 63/338,252, filed on May 4, 2022.
Prior Publication US 2023/0357190 A1, Nov. 9, 2023
Int. Cl. C07D 401/12 (2006.01); A61K 31/501 (2006.01); A61P 25/00 (2006.01)
CPC C07D 401/12 (2013.01) [A61K 31/501 (2013.01); A61P 25/00 (2018.01); C07B 2200/13 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A crystalline form of 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate form 3, characterized by having an X-ray powder diffraction obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles: 6.61°, 9.16°, 13.09°, and 14.32°.